CN107496490B - A kind of Herba Epimedii rhodiola rosea formulated product and preparation method thereof - Google Patents

A kind of Herba Epimedii rhodiola rosea formulated product and preparation method thereof Download PDF

Info

Publication number
CN107496490B
CN107496490B CN201710893479.XA CN201710893479A CN107496490B CN 107496490 B CN107496490 B CN 107496490B CN 201710893479 A CN201710893479 A CN 201710893479A CN 107496490 B CN107496490 B CN 107496490B
Authority
CN
China
Prior art keywords
total
elution
extract
meoh
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710893479.XA
Other languages
Chinese (zh)
Other versions
CN107496490A (en
Inventor
杨桂芹
王志标
刘霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Jin Yuan Pharmaceutical Co Ltd
Original Assignee
Anhui Jin Yuan Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhui Jin Yuan Pharmaceutical Co Ltd filed Critical Anhui Jin Yuan Pharmaceutical Co Ltd
Priority to CN201710893479.XA priority Critical patent/CN107496490B/en
Priority to CN201810856507.5A priority patent/CN108976264A/en
Publication of CN107496490A publication Critical patent/CN107496490A/en
Application granted granted Critical
Publication of CN107496490B publication Critical patent/CN107496490B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A61K36/296—Epimedium
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/285—Aucklandia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06—Benzopyran radicals
    • C07H17/065—Benzo[b]pyrans
    • C07H17/07—Benzo[b]pyran-4-ones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

One kind is disclosed from plant extract glycoside substance method, and the composition comprising Shorthorned Epimedium P.E and gadol extract, the extract has particularly good antiphlogistic effects compared with general extraction mixture.The composition, which can be used for preparing, can enhance immune function of human body, radiation protection and anti-inflammatory drug, health products or drink.

Description

A kind of Herba Epimedii rhodiola rosea formulated product and preparation method thereof
Technical field
The present invention relates to extractive technique fields, more particularly to extract glycoside object from Herba Epimedii using multistage column chromatography for separation Matter method, and be related to including the composition of Shorthorned Epimedium P.E and rhodiola root derivative.
Background technology
Herba Epimedii is traditional traditional tonic medicine in China, is initially recorded in《Sheng Nong's herbal classic》On, with tonifying kidney and strengthening yang, by force The effect of muscle reinforcing and bone strengthening, remove rheumatism.Epimedium herb is the dried leaf of Berberidaceae plant Herba Epimedii, and existing pharmacopeia is included shared The kinds such as Epimedium sagittatum, E. Pubescens and korean epimedium herb are more.Herba Epimedii has the work(of kidney-replenishing, strengthening the bones and muscles, wind-damp dispelling Effect.Icariin is one of monomer ingredient, and having improves cardiovascular system, adjusts endocrine, strengthen immunity, sex hormone sample The effects that, while also having positive therapeutic effect in antitumor, anti-liver poison etc..
Modern pharmacological studies have shown that Herba Epimedii can increase cardiovascular and cerebrovascular blood flow, promote hematopoiesis function, immune function and bone Metabolism has anti-aging, antitumor and other effects.
Recent researches find, the monomeric substances such as glycoside substance, Flavonoid substances and polysaccharose substance in Herba Epimedii, Improve blood vessel inner skin cell function and be better than tradition processing Herba Epimedii Chinese medicine especially, however their separation and Extraction has very big difficulty.
CN101264120B discloses a kind of barrenwort flavonol glycosides medicine materical crude slice, is made of Herba Epimedii effective part extract, Icariin content is 10-20%wt, and icariside I I contents are 2-5%wt, general flavone content 40-60%wt, total Huang Ketone includes icariside I I, newly determine towards leaves of pulse plants glycosides 1, towards the leaves of pulse plants K, icariin, towards leaves of pulse plants glycosides I, towards leaves of pulse plants glycosides third, towards leaves of pulse plants glycosides A, newly towards the leaves of pulse plants The preparation method of glycosides 2 and Hyperoside, barrenwort flavonol glycosides medicine materical crude slice includes：Weigh the korean epimedium herb overground part after crushing Point, with ethanol water refluxing extraction；Extracting solution filtering is concentrated under reduced pressure after merging, then is diluted with ethanol water, after standing from The heart, upper Diaion-HP20 resin columns are collected 60-70%v ethanol waters and elute liquid, subtracted with ethanol water gradient elution Pressure is concentrated into paste, and crushed after being dried obtains barrenwort flavonol glycosides medicine materical crude slice.
CN101843629A discloses the new application of icariin and the epimedium flavone containing icariin, and in particular to The extract prepare for treat, prevent, mitigate and/or alleviate disease related with nervous system myelin disease damage and/or Purposes in the drug of illness, or preparing for the purposes in mitigating myelinoclasis and/or promoting the drug of myelin reparation.
CN104711300A discloses a kind of preparation method of icariine, and this method includes by Shorthorned Epimedium P.E in fruit Carry out enzyme digestion reaction under the action of glue enzyme, obtain icariine, it is preferable that the pectase include polygalacturonase and Arabinofuranosidase.
CN101933550A discloses the electuary containing Herba Epimedii, and the electuary is by Herba Epimedii, ground coffee, cordyceps sinensis or pupa Cordyceps sinensis is constituted, and the weight percent of each material is as follows：Herba Epimedii and the sum of cordyceps sinensis or Cordyceps militaris account for 2-99%, ground coffee 1- 98% or Herba Epimedii 1-95%, cordyceps sinensis or Cordyceps militaris 1-96%, ground coffee 1-98%.
CN104171175A discloses a kind of Herba Epimedii tea, is prepared in following manner：A, acquisition is selected：Every year Spring acquires Epimedium brevicornum leaves, chooses sundries and old leaf；B, it finishes：It finishes 1-3 minutes at 160 DEG C~200 DEG C；C, it rubs：It will Epimedium brevicornum leaves after water-removing are rubbed, and are rubbed at item；D, fried dry：It will rub to Epimedium brevicornum leaves in stripes at 130 DEG C -90 DEG C Carry out fried dry, first through 130 DEG C of fryings of high temperature, fry to it is half-dried when gradually descend temperature regulating to 110 DEG C, gradually descend temperature adjustment again through frying Degree is to 90 DEG C, until fried dry.
CN101607976A discloses a kind of preparation method of icariin, takes epimedium herb, with the methanol of 30-90% Or alcohol reflux extraction, recycling design are condensed into medicinal extract；It is extracted repeatedly with petroleum ether, chloroform, ethyl acetate and n-butanol successively To close colourless, recycling n-butanol obtains coarse extract to dry；Then silica gel column chromatography separation and polyamide column chromatography point are carried out successively From to get icariin highly finished product, purity >=98%.
CN104688795A discloses a kind of method preparing general flavone by Herba Epimedii, and this approach includes the following steps：a. Herba Epimedii cured leaf is extracted by ethanol solution first, obtains extracting solution；B. extracting solution macropore step a obtained Resin column adsorbs, and then uses the macroporous resin column described in water and ethanol elution successively, collects last time ethanol eluate；C. will The eluent drying that step b is obtained, obtains the general flavone.
CN101669980B discloses a kind of method for extracting separating icariin and general flavone from Herba Epimedii, including with Lower step：It is first extracted using 20-40% ethyl alcohol as solvent counter current, extracting solution centrifuges, and separating liquid is respectively with microfiltration membranes except heavy Filtering and Ultra filtration membrane, then with nanofiltration membrane treatment, obtain trapped fluid；This trapped fluid is dried, 60 DEG C of drying temperature is hereinafter, dry Object moisture content≤5.0%, dried object are epimedium active constituent enriched substance, and wherein Icariin content reaches 60% or more, excessive Sheep leaves of pulse plants general flavone content reaches 80% or more, UF membrane each unit icariin, the epimedium flavone rate of transform >=98%.
CN101899077A discloses the extracting method of icariside I in Korean epimedium leaves, and step and condition are such as Under：A. the volumetric concentration that Korean epimedium leaves use is 15 times of its quality is 70% alcohol reflux 4 hours, filters out ethyl alcohol extraction Liquid is filtered by the dregs of a decoction to flow back with being that the volumetric concentration of 10 times of korean epimedium herb leaf quality is extracted 2 hours for 70% alcohol reflux Go out ethanol extract, merges filtrate twice；B. filtrate is depressurized at 50 DEG C and steams solvent, obtains extract, contained in extract Moisture be not more than the 5% of its quality；C. it uses obtained in the absolute ethyl alcohol dissolving step b of 2 times of korean epimedium herb leaf quality Concentrated hydrochloric acid is added, korean epimedium herb leaf quality gram in extract: the volume mL of concentrated hydrochloric acid is 1:0.05~0.15, in 50 DEG C of water-baths Heating 15-25 hours, left at room temperature over night, filtering；D filtrates are concentrated under reduced pressure into the 20% of its volume at 50 DEG C, and it is excessive that Korea is added Precipitation is precipitated in the distilled water of 2 times of sheep leaves of pulse plants leaf quality, is deposited in the ethanol solution for being 20% with volumetric concentration at 50 DEG C and washs, washes Being deposited at 50 DEG C after washing is dried in vacuo, and obtains icariside I powder.
CN105998140A discloses a kind of rhodiola root composition, is grouped as by following group：1.5-6g of rhodiola root, thorn Slender acanthopanax 3-27g, Radix Angelicae Sinensis 2-12g.
CN102487979B discloses a kind of Rhodiola rosea micro-powder lotus seed paste, and it includes lotus seeds 50- to constitute by weight percentage 70%, Siraitia grosvenorii 5-15%, vegetable oil 10-20%, Radix Rhodiolae micropowder 7-15%；The Radix Rhodiolae micropowder is rhodiola root ultra micro The micro mist that grain size made of pulverizer is 0.1-10 μm.
CN103012512A discloses a kind of isolation and purification method of rhodioloside in natural rhodiola root, takes natural rhodiola root It is sliced for raw material, obtains Aqueous extracts through ultrasonic water leaching, low temperature alcohol precipitation and after being concentrated under reduced pressure, then removed through solvent Removal of impurities, solvent extraction and back extraction stage obtain the rhodioloside aqueous solution of high-purity, most afterwards through reduced pressure, absolute ethyl alcohol knot Crystalline substance detaches and is dried to obtain rhodioloside product.
CN101804156A discloses the preparation process and antifatigue effect of compound rhodiola root extractive, by rhodiola root 20g-30g, sealwort 20g-30g, Schisandra chinensis 10g-20g, Herba Epimedii 10g-20g, jujube 3g-5g, what 8-10 times of coarse powder addition was measured After water impregnates 4h-6h, 100 DEG C of heating extractions, then ultrasound 1h-1.5h, temperature is 30 DEG C, power 80W, then with gauze mistake Filter, filter residue is each primary with 6 times of amounts and 4 times of amount water repetition above steps respectively again, merges filtrate three times, people is added in vacuum drying Join three alcohol type saponin(e 0.5g-1g, obtains compound rhodiola root extractive.
" Herba Epimedii Study on extraction ", Chen Luoyi etc., Chinese Journal of Modern Applied Pharmacy, 2000 (s1):12-14, research are excessive Sheep leaves of pulse plants extraction process selects L9 (3~4) orthogonal test table, knot wherein using Icarrin as Testing index Fruit shows that decocting method is close with alcohol extracting method extraction effect, and Herba Epimedii uses decocting method, and simple process is at low cost, and extraction efficiency is high, It is comparatively ideal production technology.
By the above-mentioned prior art it is found that still having number of drawbacks in the prior art, Herba Epimedii extraction in the prior art Object is actually the mixture of many kinds of substance, wherein including flavones ingredient, more than ten kind leaves of pulse plants glycosides, the leaves of pulse plants time glycosides, a variety of glucosides, the wooden fat Element, alkaloid and polysaccharide, maltol, the vertical glycosides of sand, Quercetin, icariine A, Epimedium acuminatium glycosides, anhydroicartin, isoamyl Alkene kaempferol, ginkegetin, Isoginkgetin, bilobetin, epimidin A, Hyperoside also contain certain Volatile oil, brown eleostearic acid, stearic acid, oleic acid, the leukotrienes of amount.In these substances, effective component is irregular or even some components Drug effect is relatively low, relatively low to not only result in integral medicinal effect, and since some inefficient ingredients can influence high-drug-effect ingredient instead The performance of energy.In addition, there exists a further problem in that, Shorthorned Epimedium P.E and gadol extract are mixed although having in the prior art The report of compound formulation is prepared, but is usually all the extract mixing containing complicated ingredient by two kinds, not only effect is poor, but also Synergistic effect is also poor.A kind of efficient Herba Epimedii of this field needs and gadol extract and preparation method thereof.
Invention content
To solve the above-mentioned technical problems in the prior art simultaneously, the present invention provides one kind extracting sugar from Herba Epimedii Glycoside substance method, the glucosides substance has relatively high pharmacological activity compared with other ingredients in extract, special It is not to improve immunity and anti-inflammatory efficacy.In addition, the composition comprising Shorthorned Epimedium P.E and gadol extract is additionally provided, It is acted synergistically by the compounding of the two, comprehensive pharmacological activity can be improved.For this purpose, the present invention provides following technical schemes.
In one aspect of the invention, one kind is provided from plant extract glycoside substance method, and this method uses multistage column Chromatography.
Preferably, wherein the plant is Herba Epimedii.
Preferably, in the multistage column chromatography for separation, first order column chromatography uses reverse phase silica gel column.
Most preferably, the extraction and isolated glucosides substance are lower formula (I) compound represented：
Studies have shown that the glucoside compound has compared with general flavone compound such as icariine A and B Wider bioactivity, such as anti-osteoporosis disease, androgen, anti-inflammatory and antitumaous effect.Therefore, the application makees the compound For Objective extraction compound.
For the present invention, particularly preferably, formula (I) compound represented can be made by following method, the party Method includes the following steps：
(1) MeOH (preferably 3 × 6L, each soaking time are about 20h) extraction Herba Epimedii herbal medicine powder is used at room temperature (preferably 1.18kg), combined extract is evaporated under reduced pressure to obtain brown residue (162.5g) i.e. methanol extract liquid；
(2) reverse phase silica gel column (such as RP-18 silicagel columns) is utilized, uses MeOH-H first2O mixed solutions are to the remnants Object carries out gradient elution, and to carry out pillar layer separation, preferred elution step is 0:1 (1L), 1:9 (1L), 2:8 (1L), 3:7 (1L), 4:6 (1L), 5:5 (2L), 6:4 (2L), 7:3 (1L), 1:0 (2L) then uses acetone (2L), obtains 10 successively and wash De- component is denoted as elution component A-J；
(3) elution fraction B (such as 6.5g) is subjected to chromatographic isolation on silicagel column (preferably 60cm × 5cm), used CHCl3-MeOH-H2O mixed solutions carry out gradient elution, and (gradient is preferably 20:1:0 (1L), 10:1:0 (2L), 30:8:1 (2L) and 15:6:1 (2.5L)), 4 elution components are obtained, elution fraction B1-B4 is denoted as；
(4) elution fraction B2 (such as 300.2mg) is used into MeOH-H2O(1:1) Sephadex LH-20 (preferably 100cm × 3cm) on detach, obtain 7 time elution fractions, be denoted as elution fraction B2.1-B2.7；
(5) by elution fraction B2.6 (such as 95.0mg) by silica gel CC columns (preferably 80cm × 2.5cm), eluent is EtOAc-CHCl3-MeOH-H2O(16:8:3:1), eluent is concentrated to dryness, obtains pale yellow powder (such as 6.1mg), As compound shown in formula (I).
It is analyzed through HPLC, the purity of compound shown in formula (I) is 99.7% in extract.Through1HNMR and mass spectral analysis, It is consistent with the known compound through characterization described in CAS.Positive ion mode ESI-MS shows that molecular ion peak appears in m/ z 667([M+Na]+) and 1311 ([2M+Na]+)。IR(KBr):3423, 2940,1660,1605,1512,1450。1In HNMR, In the A2B2 coupled systems that δ (H) 7.88 (d, J=8.6, H-C (2 ', 6 ')) and 7.11 (d, J=8.6, H-C (3 ', 5 ')) occur Show the presence of para-orientating group in B rings；In δ (H) 6.72 (d, J=10.0, H-C (1 "), 5.68 (d, J=10.0, H-C The serial hydrogen atom signal that (2 "), 2.14 (s, Me (4 ")) and 1.45 (s, Me (5 ")) occur shows that there are γ, γ-dimethyl Chromene ring.
Experiment finds that it is extremely difficult to obtain compound or extract shown in the formula (I) of high-purity to separation, wherein A major reason for leading to be difficult to obtain high-purity compound is the interference of albumen in extraction process, in addition, some low liters Polysaccharide is also the impurity of more difficult separation.The applicant obtains the formula of extreme high purity for the first time by above-mentioned 5 grades of column chromatography for separation (I) compound shown in.Have close level and matching relationship, setting selection and sequence non-between 5 grades of piece-rate systems Chang Guanjian.
Certainly, it will be appreciated by those of skill in the art that other elution fractions can also be used to obtain it is other valuable Substance rather than all discard.
In another aspect of this invention, a kind of composition including Shorthorned Epimedium P.E and gadol extract is provided, The Shorthorned Epimedium P.E is the glucosides substance obtained according to the above method, preferably compound shown in (I).It can also be at this Saussurea involucrata extract, wolfberry fruit extract or other extracts with required pharmacological activity are added in composition.
Preferably, the purity of the glucosides substance is more than 99.0wt%.It is highly preferred that the purity of the glucosides substance More than 99.2wt%.Most preferably, the purity of the glucosides substance is more than 99.7wt%.
The gadol extract is preferably rhodioside.Rhodioside can take the conventional method of this field to be carried It takes.It is further preferred that the gadol extract is modified gadol extract, most preferably, the gadol extract is logical It crosses and the lower formula (II) obtained or (III) compound represented is modified to rhodioside：
Compared with general natural nucleoside substance, the immunological regulation of formula (II) or (III) compound represented to normal mouse Effect becomes apparent from, and due to the introducing of electron-withdrawing group Cl and F, enhances its ability for removing free radical, can dramatically increase mouse Special antibody secreting cell number can enhance delayed allergy intensity with 50mg/ (kgd) dosage, in addition also show Go out the phagocytic function of the mixed lymphocyte reaction (MLP) to special-shaped mouse and macrophage, and can reduce to a certain extent white The activity of cytokine shows that the two is a kind of up-and-coming immunomodulator.
Substance with structure formula (II)~(III) can synthesize by the following method：MCM- is added in the reaction vessel 22 molecular sieves alternatively property catalyst, is then added chloroform solvent, then by the acetyl of natural salidroside and chloro or fluoro Chlorine (i.e. acylating agent) is with 1:1~1.3 molar ratio is added in reaction dissolvent (natural salidroside and chloro or the acetyl of fluoro Chlorine is preferably added in the form of chloroformic solution), reaction temperature is 20-30 DEG C, reaction time 10-30min, separation and drying It can be obtained the compound.This method has the advantages that high income, impurity are few.It is particularly due to the shape-selective of MCM-22 molecular sieves Effect, can significantly reduce the generation of side reaction.
In another aspect of this invention, the purposes for providing the composition, human immunity work(can be enhanced by being used to prepare Drug, health products or the drink of energy.
Preferably, the drug is Chinese traditional compound medicine.Preferably, the composition is used to prepare oral capsule, electuary Deng.The health products include oral-cavity article such as chewable tablets or lozenge.
In a preferred embodiment of the present invention, in the Chinese traditional compound medicine, Shorthorned Epimedium P.E and rhodiola root The weight ratio of derivative is 1:20-20:1.When Saussurea involucrata extract is added, the weight ratio of Saussurea involucrata extract and Shorthorned Epimedium P.E It is 1:10-1:20.Such composition has effects that particularly good anti-inflammatory, strengthen immunity and/or radiation protection.
Description of the drawings
Fig. 1 is the compound according to the embodiment of the present application 11HNMR analysis diagrams；
Fig. 2 is the suppression curve figure to PTP1B according to the compound of the embodiment of the present application 1.
Specific implementation mode
Embodiment 1：The extraction of compound shown in formula (I)
Using compound shown in following operation extraction formula (I)：(1) MeOH (3 × 6L, each soaking time are used at room temperature It is about 20h) extraction Herba Epimedii herbal medicine powder (1.18kg, raw material are purchased from the Tonghua, Jilin Province city towns Jin Chang), combined extract is subtracted Pressure evaporation obtains brown residue (162.5g) i.e. methanol extract liquid；(2) RP-18 reverse phase silica gel columns are utilized, are used first MeOH-H2O mixed solutions carry out gradient elution to the residue, to carry out pillar layer separation, elution step 0:1 (1L), 1:9 (1L), 2:8 (1L), 3:7 (1L), 4:6 (1L), 5:5 (2L), 6:4 (2L), 7:3 (1L), 1:0 (2L) then uses acetone (2L) obtains 10 elution fractions successively, is denoted as elution component A-J；(3) by 6.5g elution fractions B silicagel column (60cm × Chromatographic isolation is carried out on 5cm), using using CHCl3-MeOH-H2O mixed solutions carry out gradient elution (gradient 20:1:0 (1L), 10:1:0 (2L), 30:8:1 (2L) and 15:6:1 (2.5L)), 4 elution components are obtained, elution fraction B1-B4 is denoted as； (4) by 300.2mg elution fraction B2 MeOH-H2O(1:1) it detaches, obtains on Sephadex LH-20 (100cm × 3cm) 7 elution fractions, are denoted as elution fraction B2.1-B2.7；(5) 95.0mg elution fractions B2.6 is passed through into silica gel CC columns (80cm × 2.5cm), eluent EtOAc-CHCl3-MeOH-H2O(16:8:3:1), eluent is concentrated to dryness, obtains 6.1mg Compound shown in pale yellow powder, as formula (I).
Embodiment 2：Compound shown in formula (I) inhibits PTP 1B (PTP1B) and α-glucuroide Ability.Specific rejection ability is as shown in table 1 below：
Table 1：Compound shown in formula (I) inhibits the ability of PTP 1B (PTP1B) and alpha-glucosidase
In the test, malol and acarbose are used as positive reference substance.Test method is according to standard method with micro Method carries out, specifically：This system reaction 100 μ L, PTP1B substrates p-NPP of total volume is dissolved in buffer solution (50mmolL- 1HEPES pH value 7.3,100mmolL-1NaCl, 0.1%BSA, 1mmolL-1DTT in), pNPP reactions are final concentration of 5mmol·L-1, extract dissolves by DMSO, takes 0.5~1 μ L of enzyme solution, diluted and mixed well by 250 μ L PBS buffer solution, taken The 160 μ L of enzyme solution diluted add to 96 orifice plates, add 1 μ L of DMSO (extract solvent), soft mixing, at the same by PTP1B with 35mmolL is added after 96 orifice plates incubation at room temperature 5min is added in extract-1P-NPP 20 μ L, 37 DEG C are protected from light 30min, and 0.5 mol·L-1Sodium hydroxide terminates reaction, and microplate reader reads absorbance (A) value at wavelength 405nm, and phase is calculated according to normalized form Answer half-inhibition concentration (IC50) value；Also make suppression curve of the compound to PTP1B simultaneously (referring to Fig. 2).
Embodiment 3：Include the manufacture of the capsule of Shorthorned Epimedium P.E and gadol extract
Including the Shorthorned Epimedium P.E of embodiment 1 and the capsule manufacturing method of gadol extract, wherein the rhodiola root Extract is compound shown in formula (II), and the weight ratio of Shorthorned Epimedium P.E and rhodiola root derivative is 5:1, each capsule contains There are 0.1g contents.
Embodiment 4：Anti-inflammatory effect of the capsule of testing example 3 to mice auricle swelling
Kunming mice 40, weight 150-220g is taken, half male and half female is randomly divided into 5 groups, i.e. model group, conventional extract Capsules group (0.08gkg-1, control group, wherein Shorthorned Epimedium P.E according to described in CN101264120B method obtain, It is remaining same as Example 3), 3 Capsules group (0.08gkg of embodiment-1), daily gastric infusion 1 time, continuous 4d, in last dose 30min afterwards, every mouse right ear exterior feature two sides are applied 20 μ L of dimethylbenzene, cause mice auricle swelling model, compared with left ear, Cervical dislocation puts to death mouse after 20min, two ears is cut along auricle baseline, with diameter 6mm card punch respectively in left and right ear antimere Round auricle is laid, precise weighing using its difference as inflammatory swelling degree (mg), and calculates swelling inhibiting rate.
Swelling inhibiting rate=(model group swelling-administration group swelling)/model group swelling × 100%
Compared with model group mice ear degree, the compound capsule group of embodiment 3 is compared with compareing each dosage group of Capsules group The significant difference of inhibiting effect of mice ear caused by paraxylene shows to prompt FUFANG XUELIAN JIAONANG that can mitigate diformazan Benzene causes mice auricle swelling degree, has certain anti-inflammatory effect, see the table below 2：
Table 2：Compound capsule paraxylene causes the influence of mice auricle swelling
Group Dosage/gkg-1 Swelling/mg Inhibiting rate/%
Model group - 8.55±1.22 -
Embodiment 3 0.08 4.01±0.92 53.10%
Control group 0.08 5.96±1.23 30.29%
By above example clearly it can be seen from the present invention Shorthorned Epimedium P.E to PTP1B) and alpha-glucosidase With good inhibiting effect, and compared with the existing technology in extract (i.e. crude extract, the mixture of Multiple components) It compares, there is apparent better antiphlogistic effects.
This written description discloses the present invention, including optimal mode using example, and also enables those skilled in the art It manufactures and using the present invention.The present invention can patentable scope be defined by the claims, and may include this field skill Other examples that art personnel expect.If this other examples have not different from the structural elements of the literal language of claims Element, or if this other examples include with equivalent structure element of the literal language of claims without substantial differences, Then this other examples are intended within the scope of claims.In the case where inconsistent degree will not be caused, by reference to It will be incorporated herein in place of all references referred to herein.

Claims (5)

1. a kind of extracting glycoside substance method from Herba Epimedii, this method uses multistage column chromatography for separation, the extraction and separation Obtained glucosides substance is lower formula (I) compound represented：
This approach includes the following steps：
(1) Herba Epimedii herbal medicine powder is extracted with MeOH at room temperature, combined extract is evaporated under reduced pressure to obtain brown residue i.e. Methanol extract liquid；
(2) reverse phase silica gel column is utilized, uses MeOH-H first2O mixed solutions carry out gradient elution to the residue, to carry out Pillar layer separation, elution step 0:1 total 1L, 1:9 total 1L, 2:8 total 1L, 3:7 total 1L, 4:6 total 1L, 5:5 total 2L, 6:4 total 2L, 7:3 total 1L, 1:Then 0 total 2L uses acetone 2L, obtains 10 elution fractions successively, be denoted as elution component A-J；
(3) elution fraction B is subjected to chromatographic isolation on a silica gel column, uses CHCl3-MeOH-H2O mixed solutions carry out gradient and wash It is de-, gradient 20:1:0 total 1L, 10:1:0 total 2L, 30:8:1 total 2L and 15:6:1 total 2.5L obtains 4 elution components, It is denoted as elution fraction B1-B4；
(4) by elution fraction B2 with 1:1 MeOH-H2O is detached on Sephadex LH-20, obtains 7 elution fractions, note For elution fraction B2.1-B2.7；
(5) elution fraction B2.6 is passed through into silica gel CC columns, eluent 16:8:3:1 EtOAc-CHCl3-MeOH-H2O will be washed De- liquid is concentrated to dryness, and obtains pale yellow powder, as compound shown in formula (I).
2. a kind of composition including Shorthorned Epimedium P.E and gadol extract, the Shorthorned Epimedium P.E is to be wanted according to right The glucosides substance for asking the method described in 1 to obtain, the gadol extract are lower formula (II) compound represented：
3. composition according to claim 2, wherein the purity of the glycoside substance is more than 99.0wt%.
4. composition according to claim 3, wherein the purity of the glycoside substance is more than 99.2wt%.
5. composition according to claim 4, wherein the purity of the glycoside substance is more than 99.7wt%.
CN201710893479.XA 2017-09-25 2017-09-25 A kind of Herba Epimedii rhodiola rosea formulated product and preparation method thereof Active CN107496490B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710893479.XA CN107496490B (en) 2017-09-25 2017-09-25 A kind of Herba Epimedii rhodiola rosea formulated product and preparation method thereof
CN201810856507.5A CN108976264A (en) 2017-09-25 2017-09-25 A kind of kidney tonifying, benefiting essence-blood, radiation protection saussurea involucrata Herba Epimedii root of kirilow rhodiola Chinese medicine composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710893479.XA CN107496490B (en) 2017-09-25 2017-09-25 A kind of Herba Epimedii rhodiola rosea formulated product and preparation method thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810856507.5A Division CN108976264A (en) 2017-09-25 2017-09-25 A kind of kidney tonifying, benefiting essence-blood, radiation protection saussurea involucrata Herba Epimedii root of kirilow rhodiola Chinese medicine composition

Publications (2)

Publication Number Publication Date
CN107496490A CN107496490A (en) 2017-12-22
CN107496490B true CN107496490B (en) 2018-09-11

Family

ID=60699924

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710893479.XA Active CN107496490B (en) 2017-09-25 2017-09-25 A kind of Herba Epimedii rhodiola rosea formulated product and preparation method thereof
CN201810856507.5A Pending CN108976264A (en) 2017-09-25 2017-09-25 A kind of kidney tonifying, benefiting essence-blood, radiation protection saussurea involucrata Herba Epimedii root of kirilow rhodiola Chinese medicine composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810856507.5A Pending CN108976264A (en) 2017-09-25 2017-09-25 A kind of kidney tonifying, benefiting essence-blood, radiation protection saussurea involucrata Herba Epimedii root of kirilow rhodiola Chinese medicine composition

Country Status (1)

Country Link
CN (2) CN107496490B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111329906A (en) * 2020-04-03 2020-06-26 丛艳东 Chinese medicine for preventing and treating cardiovascular and cerebrovascular diseases
CN111303222A (en) * 2020-04-14 2020-06-19 福建中医药大学 Salidroside derivative and preparation method and application thereof
CN112552356A (en) * 2020-06-29 2021-03-26 郑州福瑞堂制药有限公司 Method for preparing icariin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1911103B (en) * 2005-08-08 2011-07-27 天津丹溪国药研究所 Health-care food for improving human body physical agility and endurance
CN101607976B (en) * 2008-06-19 2013-09-04 贵州省中国科学院天然产物化学重点实验室 Method for preparing icariin
CN101669980B (en) * 2008-09-09 2011-08-17 劲牌有限公司 Method for extracting and separating icariin and flavone from epimedium herb
CN101899077A (en) * 2010-06-23 2010-12-01 吉林大学 Extraction method and application of icariside I in Korean epimedium herb leaf
CN103087984B (en) * 2011-11-01 2016-03-23 北京清美联创干细胞科技有限公司 A kind of have the Chinese medicine composition and application thereof that promote mescenchymal stem cell proliferation function

Also Published As

Publication number Publication date
CN107496490A (en) 2017-12-22
CN108976264A (en) 2018-12-11

Similar Documents

Publication Publication Date Title
EP1463412B1 (en) Composition comprising wenguanguo extracts, methods for preparing same and uses therof
CN112870236B (en) Flavone effective part of abelmoschus manihot and preparation method and application thereof
CN107496490B (en) A kind of Herba Epimedii rhodiola rosea formulated product and preparation method thereof
CN102114102B (en) Traditional Chinese medicine extract mixed preparation and application thereof
CN102212093A (en) Flavonoid glycoside compounds, method for preparing same and application
CN102370695A (en) Qinglongyi active extract, its preparation method and its application
CN107137438B (en) The purposes of wintersweet platymiscium anti-mycobacterium tuberculosis
CN101474350B (en) Method for extracting total saponin in asparagus and use thereof
CN101755953A (en) Green tea extract with blood sugar reducing effect and preparation method thereof
CN102875615B (en) Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf
CN101880303A (en) Method for extracting bitter gourd saponin from bitter gourd
CN107325147A (en) The screening technique of fulvoushair honeysuckle flower moderate resistance hypertensin conversion enzyme activity composition
CN1312170C (en) Technique of preparing extract product of Radde Anemone Rhizome extract, and its application in preparing medication of treating cancer
CN105192820A (en) Blood-fat-reducing cordyceps militaris polysaccharide beverage and preparing method thereof
CN105412613B (en) A kind of formula and its processing method for senile dementia
CN113368156A (en) Fructus forsythiae leaf active ingredient and application thereof in preparation of anti-Alzheimer disease drugs
CN101422518B (en) Preparation method of loquat flower extract
CN104288223A (en) Method for preparing total flavonoids of Chinese mosla herb and application of total flavonoids of Chinese mosla herb
CN114767695B (en) Extraction method and application of allium fistulosum lactone
CN110801469A (en) Functional food for regulating blood sugar and preparation method thereof
CN109223739A (en) A kind of composition and its preparation method and application
CN103083376B (en) Can be used for the Rhizoma Ligustici extract for the treatment of rhinitis
CN109021045A (en) The method for separating hemp glycosides, Yi Quercetin skin glycosides and chlorogenic acid simultaneously in largeleaf poacynum leaf leaf
GB2364640A (en) Composition for the treatment of peptic ulcer comprising American ginseng
TWI222357B (en) Anti-ulcer pharmaceutical composition and the preparation and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant